Mantle cell lymphoma epidemiology and demographics: Difference between revisions
No edit summary |
|||
| Line 9: | Line 9: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
* The annual incidence of this disease has increased during recent decades to 1–2/100 000 recently. | * The annual incidence of this disease has increased during recent decades to 1–2/100 000 recently.<ref>{{Cite journal | ||
| author = [[M. Dreyling]], [[C. Geisler]], [[O. Hermine]], [[H. C. Kluin-Nelemans]], [[S. Le Gouill]], [[S. Rule]], [[O. Shpilberg]], [[J. Walewski]] & [[M. Ladetto]] | |||
| title = Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |||
| journal = [[Annals of oncology : official journal of the European Society for Medical Oncology]] | |||
| volume = 25 Suppl 3 | |||
| pages = iii83–iii92 | |||
| year = 2014 | |||
| month = September | |||
| doi = 10.1093/annonc/mdu264 | |||
| pmid = 25210087 | |||
}}</ref> | |||
===Prevalence=== | ===Prevalence=== | ||
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | *The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | ||
Revision as of 19:06, 14 November 2018
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma epidemiology and demographics |
|
Mantle cell lymphoma epidemiology and demographics in the news |
|
Risk calculators and risk factors for Mantle cell lymphoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]
Overview
MCL accounts for 4–8% of all adult non-Hodgkin’s lymphomas (NHL).
Epidemiology and Demographics
Incidence
- The annual incidence of this disease has increased during recent decades to 1–2/100 000 recently.[1]
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Overview
Mantle cell lymphoma is a rare disease that tends to affect elderly patients > 60 years. In 2015, the incidence of mantle cell lymphoma was estimated to be 1.3 cases per 100,000 individuals in the United States. The prevalence of mantle cell lymphoma is estimated to be 5 cases per 100,000 individuals in the United States. Males are more commonly affected with mantle cell lymphoma than females. The male to female ratio is approximately 4 to 1.
Epidemiology and Demographics
Incidence
In 2015, the incidence of mantle cell lymphoma was estimated to be 1.3 cases per 100,000 individuals in the United States.
Prevalence
- The prevalence of mantle cell lymphoma is estimated to be 5 cases per 100,000 individuals in the United States.
- The prevalence seems to be somewhat higher in Europe.
Age
Mantle cell lymphoma tends to affect elderly patients > 60 years.[2]
Gender
Males are more commonly affected with mantle cell lymphoma than females. The male to female ratio is approximately 4 to 1.
References
- ↑ M. Dreyling, C. Geisler, O. Hermine, H. C. Kluin-Nelemans, S. Le Gouill, S. Rule, O. Shpilberg, J. Walewski & M. Ladetto (2014). "Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of oncology : official journal of the European Society for Medical Oncology. 25 Suppl 3: iii83–iii92. doi:10.1093/annonc/mdu264. PMID 25210087. Unknown parameter
|month=ignored (help) - ↑ National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov